Global Opioid Induced Constipation Drugs Market to 2022 Strategies and Forecast Till:Credence Research

Buy Now
Global Opioid Induced Constipation Drugs Market -
Growth, Share, Opportunities, Competitive Analysis,
and Forecast, 2016-2022
Report Description:
The latest market report published by Credence Research “Global Opioid Induced Constipation
Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,”
the opioid induced constipation drugs market was valued at USD 1,933.2 Mn in 2015, and is
expected to reach USD 2,779.24 Mn by 2022, expanding at a CAGR of 4.6% from 2016 to 2022.
Browse the full report Opioid Induced Constipation Drugs Market - Growth, Share,
Opportunities, Competitive Analysis, and Forecast, 2016–2022 report at
http://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market
Market Insights
Alarming growth in opioid prescription for non-cancer pain has been a phenomenal event in the
previous decade. As per the recent estimates, more than 40% of opioid consumers experience
constipation and GI symptoms as side effects of opioid drugs. Rising pool of opioid users will
lead to the growth in opioid induced constipation (OIC) prevalence thus contributing to OIC
drugs market growth. The global opioid induced constipation drugs market was valued at USD
1,933.2 Mn in 2014 and is expected to reach USD 2,779.2 Mn by 2022 with the market growing
at a CAGR of 4.6% during 2016-2022.
Methylnaltrexone bromide, lubiprostone and naloxegol are the three drugs currently indicated
for OIC treatment. Among these, methylnaltrexone bromide holds the largest market size and is
expected to progress with a CAGR of 2.9% during the forecast period. Relistor from Salix
Pharmaceuticals is indicated for treatment of OIC in patients with advanced illness receiving
palliative care, particularly when standard laxative therapy proves insufficient. Lubiprostone
under the brandname Amitiza is indicated for treating OIC, where it major indication is for
chronic idiopathic constipation (CIC). Lubiprostone is expected that the segment will take over
the market share of methylnaltrexone bromide. Additionally, naloxegol is expected to grow at
highest CAGR over the forecast period. The drug is under testing for various patient types such
as pregnant women and patients less than 17 years of age. Thus, future approvals are expected
to lead the market.
Browse All Reports Of This Category:
http://www.credenceresearch.com/industry/pharmaceuticals-market
http://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market

Buy Now
North America is the dominant regional OIC drugs market through the forecast period. Early
bird approval of OIC drugs by the USFDA and high consumption of opioids in the US are the
prime growth factors for the OIC drugs market in North America. On the other hand, Germany,
UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the
developed countries across the world, predominantly North America and Europe are the key
consumers of OIC drugs.
On the basis of prescription type the market is segmented into prescribed drugs and over the
counter or OTC drugs. Constipation is never considered as a disease but a syndrome or a side
effect; people are less likely to visit doctors to get prescription for constipation. Thus, the OIC
drugs market is dominated by over the counter prescription with 65.87% market share in 2014.
The OTC drug market will continue to dominate the market growing at the highest CAGR of
4.9% during 2016-2022.
Click Here To Download Detail Report: http://www.pdfdevices.com
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non legislative associations, and not-for-benefits. We offer our
customers some assistance with making enduring enhancements to their execution and
understand their most imperative objectives. Over almost a century, we've manufactured a
firm extraordinarily prepared to this task.
Contact Us:
Media Contact
Name: Chris Smith (Global Sales Manager )
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com
http://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market

http://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market
Buy Now